+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Blood Line for Hemodiafiltration Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Blood Line for Hemodiafiltration Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
New

Blood Line for Hemodiafiltration Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 192 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 6079174
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
Hemodiafiltration blood lines represent a critical component in delivering effective and safe extracorporeal renal replacement therapy. By facilitating the connection between a patient’s vascular access and the hemodiafiltration device, these blood lines ensure efficient removal of waste products, fluid balance, and hemodynamic stability. Over the past decade, the sector has witnessed significant technological refinements, driven by a deeper understanding of biocompatible materials, precision engineering, and patient-centric design. As healthcare providers seek to optimize treatment outcomes and enhance patient comfort, the demand for advanced blood line solutions has intensified. This executive summary synthesizes the latest developments in product innovation, regulatory influences, and strategic imperatives, equipping decision-makers with actionable intelligence. Through a structured exploration of transformative shifts, tariff impacts, segmentation nuances, regional dynamics, and competitive strategies, readers will gain a holistic perspective on where the hemodiafiltration blood line industry stands today and the forces shaping its trajectory. Whether you are an R&D executive, procurement leader, or clinical specialist, this overview provides the foundational insights necessary to navigate the evolving landscape and align organizational objectives with emerging opportunities in renal care.

Key Drivers and Technological Shifts Reshaping Blood Line Solutions

The hemodiafiltration blood line sector is undergoing a profound transformation propelled by several converging factors. First, advances in material science have accelerated the adoption of bio-compatible polymers that minimize inflammatory responses and improve clot prevention. Innovations such as pre-curved arteriovenous fistula tubing and DEHP-free PVC formulations exemplify this shift toward safer, more patient-friendly devices. Second, regulatory frameworks are tightening quality and safety standards, prompting manufacturers to enhance traceability, sterility validation, and supply chain transparency. At the same time, the rise of home-based hemodialysis has spurred demand for user-friendly blood line assemblies that simplify setup, reduce training burdens, and support remote monitoring. Additionally, digital integration-including smart connectors and infusion tracking systems-enables real-time performance metrics and predictive maintenance alerts, reinforcing clinical confidence. Collaboration between device makers and nephrology centers is further fostering iterative improvements based on frontline feedback. As a result, the sector is moving away from one-size-fits-all models toward customizable configurations that address diverse clinical scenarios, patient age groups, and care settings. This convergence of technological, regulatory, and clinical imperatives is setting the stage for a new era of precision extracorporeal therapy.

Understanding the Cumulative Impact of United States Tariffs 2025 on Hemodiafiltration Supplies

Beginning in early 2025, the imposition of revised tariffs on imported medical components has introduced a new layer of complexity to hemodiafiltration supply chains. Materials such as medical-grade silicone and specialized polyurethanes, frequently sourced from global suppliers, now carry higher duties, which in turn compress manufacturer margins. To address these pressures, some producers have accelerated efforts to vertically integrate polymer extrusion and tubing assembly, thereby regaining cost control and protecting quality standards. At the same time, distributors are renegotiating long-term contracts and exploring duty drawback programs to offset incremental expenses. Clinicians and procurement teams are feeling the ripple effects: price adjustments are under review, and inventory stocking strategies are being recalibrated to account for lead-time variability. Meanwhile, strategic partnerships between device manufacturers and logistics providers are being revisited to optimize customs clearance processes. Despite these headwinds, the industry remains committed to maintaining product integrity and supply reliability. Collaborative initiatives, such as pooled procurement and joint sourcing alliances, are emerging as viable pathways to mitigate tariff-induced cost escalation and ensure uninterrupted patient access to advanced hemodiafiltration solutions.

Comprehensive Segmentation Insights for Hemodiafiltration Blood Line Markets

A granular examination of the blood line landscape reveals distinct patterns across product types, materials, patient demographics, end users, and technological tiers. Arteriovenous fistula blood lines dominate the clinical space, with bio-compatible, pre-curved, and standard variants tailored to diverse vascular anatomies and access points. Equally, arteriovenous graft blood lines have evolved from generic PTFE designs to incorporate low-allergenicity coatings that reduce thrombogenicity and extend graft patency. Central venous catheter blood lines, available as single, double, or triple lumen assemblies, support acute filtration protocols and facilitate concurrent infusions when needed. Material selection further differentiates offerings: polyurethane lines optimized for biocompatibility coexist with DEHP-free PVC options prized for flexibility and cost efficiency, while silicone tubing addresses the highest purity requirements in sensitive patient groups. Patient age segmentation underscores the need for specialized kits; adult lines address flow demands of young to middle-aged adults, whereas pediatric, infant, and toddler configurations incorporate scaled connectors and reduced priming volumes. Geriatric solutions, from early to late phase modules, integrate enhanced anticoagulant coatings and data-driven efficacy markers. End-user contexts shape design priorities: dialysis clinics prioritize high-throughput durability, home-based systems emphasize simplified hook-up procedures and remote diagnostic feedback, and hospitals require modular compatibility with a range of hemodialysis stations. Finally, technology tiers span from standard hemodialysis blood lines to advanced high-efficiency and high-flux variants, each engineered to balance clearance performance with hemocompatibility. Together, these segmentation insights highlight the industry’s shift toward precision-engineered, context-aware blood line ecosystems.

Region-Specific Dynamics Shaping Hemodiafiltration Blood Line Demand

Demand patterns in the Americas reflect a mature infrastructure with established reimbursement pathways for home hemodialysis and clinic-based therapies. Providers in this region are investing heavily in bio-compatible innovations and digital performance tracking to meet stringent regulatory and payer requirements. Meanwhile, Europe, Middle East & Africa present a heterogeneous landscape: Western European nations emphasize sustainability and single-use reduction, leading to interest in recyclable polymer blends, whereas emerging markets in the Middle East and Africa prioritize affordability and reliable distribution channels to expand access. In Asia-Pacific, rapid urbanization and rising incidence of chronic kidney disease are driving capacity expansions in both hospital and outpatient settings. Manufacturers are tailoring line lengths, connector standards, and packaging solutions to regional anatomical norms and sterilization protocols. Cross-border trade agreements and regional harmonization efforts are gradually streamlining regulatory approvals, enabling faster product launches and fostering local manufacturing partnerships. As a result, each geography demands nuanced go-to-market approaches: North America focuses on value-added services and digital integration, EMEA balances sustainability with budget constraints, and Asia-Pacific underscores scalability and localized support frameworks.

Competitive Landscape: Profile of Leading Hemodiafiltration Blood Line Providers

Leading players display differentiated strategies to capture value in the hemodiafiltration blood line segment. A prominent Japanese innovator has leveraged proprietary polymer coatings to reduce thrombogenic risk, while a global German-based medical technology provider emphasizes modular systems integrated with its wider circulatory care portfolio. A U.S.-headquartered manufacturer combines a broad device suite with subscription-based maintenance services, enhancing lifetime customer engagement. A specialized group in China focuses on cost-effective assembly lines, serving growing domestic and exporter markets with locally compliant designs. A major European integrated renal care company drives standardization across its global network, embedding advanced filtration tubing in its full-service dialysis centers. Meanwhile, a leading Japanese multi-disciplinary device firm is expanding its footprint through strategic acquisitions and joint ventures in emerging markets. An American diversified healthcare titan is positioning blood line innovations as part of end-to-end patient management platforms. A pioneering Japanese specialist is optimizing its filtration membranes and fluidics expertise to deliver next-generation tubing. Another Japanese manufacturer with global reach maintains strong R&D pipelines in silicone and polyurethane composites. Finally, a subsidiary of one of the largest renal care providers offers seamless integration of disposable blood lines with in-home dialysis machines, backed by expert training and remote support.

Strategic Recommendations for Industry Leaders in Hemodiafiltration Blood Line Segment

Industry leaders must adopt a multi-pronged strategy to thrive amid evolving clinical requirements, cost pressures, and regulatory demands. First, strengthening partnerships with polymer innovators and academic centers will accelerate biocompatibility breakthroughs and enable differentiated material offerings. Concurrently, diversifying supply chains through dual-sourcing agreements and near-shoring initiatives can reduce exposure to tariff volatility and logistical disruptions. Second, investing in digital connectivity-such as smart tubing connectors that relay real-time flow metrics-will enhance treatment personalization and support value-based reimbursement models. Third, co-developing turnkey home dialysis kits with integrated training modules and telehealth interfaces will address the growing preference for in-home therapies. Fourth, forging alliances with regional distributors to tailor packaging, labeling, and sterilization processes ensures regulatory compliance and market penetration in diverse geographies. Fifth, aligning product roadmaps with evolving clinical guidelines around high-flux and high-efficiency filters positions companies to meet future care standards. Sixth, offering flexible commercial models, including equipment-as-a-service and volume-based licensing, can foster long-term customer loyalty. Finally, maintaining transparency in quality management, while proactively engaging with health authorities on safety data and post-market surveillance, will reinforce trust and sustain market access.

Concluding Perspectives on the Hemodiafiltration Blood Line Sector

The hemodiafiltration blood line industry stands at a pivotal juncture where innovation, regulation, and patient needs converge. Technological progress in materials and smart integration is redefining device performance, while tariff landscapes and regional complexities are influencing strategic priorities. Stakeholders who align R&D efforts with end-user demands, fortify resilient supply chains, and embrace collaborative commercialization models will secure competitive advantage. By prioritizing biocompatibility, digital enablement, and patient-centric design, manufacturers can enhance clinical outcomes and operational efficiency. Simultaneously, engaging proactively with regulatory bodies and payer systems will streamline market access and support sustainable growth. As the push for home-based therapies intensifies, companies that develop comprehensive support ecosystems-combining hardware, software, and service-will capture emerging opportunities in decentralized care. Ultimately, the organization that navigates these multifaceted dynamics with agility and foresight will emerge as a trusted partner in the global fight against renal disease.

Market Segmentation & Coverage

This research report categorizes the Blood Line for Hemodiafiltration Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Arteriovenous (AV) Fistula Blood Lines
    • Bio-Compatible AV Fistula Blood Lines
    • Pre-Curved AV Fistula Blood Lines
    • Standard AV Fistula Blood Lines
  • Arteriovenous (AV) Graft Blood Lines
    • Bio-Compatible AV Graft Blood Lines
    • Standard AV Graft Blood Lines
  • Central Venous Catheter (CVC) Blood Lines
    • Double Lumen CVC Blood Lines
    • Single Lumen CVC Blood Lines
    • Triple Lumen CVC Blood Lines
  • Polyurethane Blood Lines
    • Biocompatible Polyurethane Blood Lines
    • Low-Allergenicity Polyurethane Blood Lines
  • Polyvinyl Chloride (PVC) Blood Lines
    • DEHP-Free PVC Blood Lines
    • Standard PVC Blood Lines
  • Silicone Blood Lines
    • Biocompatible Silicone Blood Lines
    • Medical-Grade Silicone Blood Lines
  • Adult Blood Lines
    • Middle-Aged Adult Blood Lines
    • Young Adult Blood Lines
  • Geriatric Blood Lines
    • Early Geriatric Blood Lines (65-75)
      • 65-70 Years
      • 71-75 Years
    • Late Geriatric Blood Lines (76-85)
      • Medical Grade
        • Biocompatibility
        • Efficacy Data
  • Pediatric Blood Lines
    • Child Blood Lines
    • Infant Blood Lines
    • Toddler Blood Lines
  • Dialysis Clinics
    • Independent Dialysis Clinics
    • Networked Dialysis Clinics
  • Home Hemodialysis
    • Assisted Home Hemodialysis
    • Remote Home Hemodialysis
  • Hospitals
    • Private Hospitals
    • Public Hospitals
    • Tertiary Hospitals
  • Advanced Hemodialysis Blood Lines
    • High Efficiency Blood Lines
    • High Flux Blood Lines
    • Low Flux Blood Lines
  • Standard Hemodialysis Blood Lines

This research report categorizes the Blood Line for Hemodiafiltration Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Blood Line for Hemodiafiltration Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Asahi Kasei Corporation
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • DMed Healthcare Group Limited
  • Fresenius Medical Care AG & Co. KGaA
  • JMS Co., Ltd.
  • Medtronic plc
  • Nikkiso Co., Ltd.
  • Nipro Corporation
  • NxStage Medical, Inc. (a Fresenius Medical Care company)

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Blood Line for Hemodiafiltration Market, by Product Type
8.1. Introduction
8.2. Arteriovenous (AV) Fistula Blood Lines
8.2.1. Bio-Compatible AV Fistula Blood Lines
8.2.2. Pre-Curved AV Fistula Blood Lines
8.2.3. Standard AV Fistula Blood Lines
8.3. Arteriovenous (AV) Graft Blood Lines
8.3.1. Bio-Compatible AV Graft Blood Lines
8.3.2. Standard AV Graft Blood Lines
8.4. Central Venous Catheter (CVC) Blood Lines
8.4.1. Double Lumen CVC Blood Lines
8.4.2. Single Lumen CVC Blood Lines
8.4.3. Triple Lumen CVC Blood Lines
9. Blood Line for Hemodiafiltration Market, by Material Type
9.1. Introduction
9.2. Polyurethane Blood Lines
9.2.1. Biocompatible Polyurethane Blood Lines
9.2.2. Low-Allergenicity Polyurethane Blood Lines
9.3. Polyvinyl Chloride (PVC) Blood Lines
9.3.1. DEHP-Free PVC Blood Lines
9.3.2. Standard PVC Blood Lines
9.4. Silicone Blood Lines
9.4.1. Biocompatible Silicone Blood Lines
9.4.2. Medical-Grade Silicone Blood Lines
10. Blood Line for Hemodiafiltration Market, by Patient Age Group
10.1. Introduction
10.2. Adult Blood Lines
10.2.1. Middle-Aged Adult Blood Lines
10.2.2. Young Adult Blood Lines
10.3. Geriatric Blood Lines
10.3.1. Early Geriatric Blood Lines (65-75)
10.3.1.1. 65-70 Years
10.3.1.2. 71-75 Years
10.3.2. Late Geriatric Blood Lines (76-85)
10.3.2.1. Medical Grade
10.3.2.1.1. Biocompatibility
10.3.2.1.2. Efficacy Data
10.4. Pediatric Blood Lines
10.4.1. Child Blood Lines
10.4.2. Infant Blood Lines
10.4.3. Toddler Blood Lines
11. Blood Line for Hemodiafiltration Market, by End User
11.1. Introduction
11.2. Dialysis Clinics
11.2.1. Independent Dialysis Clinics
11.2.2. Networked Dialysis Clinics
11.3. Home Hemodialysis
11.3.1. Assisted Home Hemodialysis
11.3.2. Remote Home Hemodialysis
11.4. Hospitals
11.4.1. Private Hospitals
11.4.2. Public Hospitals
11.4.3. Tertiary Hospitals
12. Blood Line for Hemodiafiltration Market, by Technology Type
12.1. Introduction
12.2. Advanced Hemodialysis Blood Lines
12.2.1. High Efficiency Blood Lines
12.2.2. High Flux Blood Lines
12.2.3. Low Flux Blood Lines
12.3. Standard Hemodialysis Blood Lines
13. Americas Blood Line for Hemodiafiltration Market
13.1. Introduction
13.2. Argentina
13.3. Brazil
13.4. Canada
13.5. Mexico
13.6. United States
14. Asia-Pacific Blood Line for Hemodiafiltration Market
14.1. Introduction
14.2. Australia
14.3. China
14.4. India
14.5. Indonesia
14.6. Japan
14.7. Malaysia
14.8. Philippines
14.9. Singapore
14.10. South Korea
14.11. Taiwan
14.12. Thailand
14.13. Vietnam
15. Europe, Middle East & Africa Blood Line for Hemodiafiltration Market
15.1. Introduction
15.2. Denmark
15.3. Egypt
15.4. Finland
15.5. France
15.6. Germany
15.7. Israel
15.8. Italy
15.9. Netherlands
15.10. Nigeria
15.11. Norway
15.12. Poland
15.13. Qatar
15.14. Russia
15.15. Saudi Arabia
15.16. South Africa
15.17. Spain
15.18. Sweden
15.19. Switzerland
15.20. Turkey
15.21. United Arab Emirates
15.22. United Kingdom
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Asahi Kasei Corporation
16.3.2. B. Braun Melsungen AG
16.3.3. Baxter International Inc.
16.3.4. DMed Healthcare Group Limited
16.3.5. Fresenius Medical Care AG & Co. KGaA
16.3.6. JMS Co., Ltd.
16.3.7. Medtronic plc
16.3.8. Nikkiso Co., Ltd.
16.3.9. Nipro Corporation
16.3.10. NxStage Medical, Inc. (a Fresenius Medical Care company)
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. BLOOD LINE FOR HEMODIAFILTRATION MARKET MULTI-CURRENCY
FIGURE 2. BLOOD LINE FOR HEMODIAFILTRATION MARKET MULTI-LANGUAGE
FIGURE 3. BLOOD LINE FOR HEMODIAFILTRATION MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY MATERIAL TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY MATERIAL TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. BLOOD LINE FOR HEMODIAFILTRATION MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. BLOOD LINE FOR HEMODIAFILTRATION MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BLOOD LINE FOR HEMODIAFILTRATION MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY ARTERIOVENOUS (AV) FISTULA BLOOD LINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY BIO-COMPATIBLE AV FISTULA BLOOD LINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY PRE-CURVED AV FISTULA BLOOD LINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY STANDARD AV FISTULA BLOOD LINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY ARTERIOVENOUS (AV) FISTULA BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY ARTERIOVENOUS (AV) GRAFT BLOOD LINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY BIO-COMPATIBLE AV GRAFT BLOOD LINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY STANDARD AV GRAFT BLOOD LINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY ARTERIOVENOUS (AV) GRAFT BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY CENTRAL VENOUS CATHETER (CVC) BLOOD LINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY DOUBLE LUMEN CVC BLOOD LINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY SINGLE LUMEN CVC BLOOD LINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY TRIPLE LUMEN CVC BLOOD LINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY CENTRAL VENOUS CATHETER (CVC) BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY MATERIAL TYPE, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY POLYURETHANE BLOOD LINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY BIOCOMPATIBLE POLYURETHANE BLOOD LINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY LOW-ALLERGENICITY POLYURETHANE BLOOD LINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY POLYURETHANE BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY POLYVINYL CHLORIDE (PVC) BLOOD LINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY DEHP-FREE PVC BLOOD LINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY STANDARD PVC BLOOD LINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY POLYVINYL CHLORIDE (PVC) BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY SILICONE BLOOD LINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY BIOCOMPATIBLE SILICONE BLOOD LINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY MEDICAL-GRADE SILICONE BLOOD LINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY SILICONE BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY ADULT BLOOD LINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY MIDDLE-AGED ADULT BLOOD LINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY YOUNG ADULT BLOOD LINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY ADULT BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY GERIATRIC BLOOD LINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY EARLY GERIATRIC BLOOD LINES (65-75), BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY 65-70 YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY 71-75 YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY EARLY GERIATRIC BLOOD LINES (65-75), 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY LATE GERIATRIC BLOOD LINES (76-85), BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY MEDICAL GRADE, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY BIOCOMPATIBILITY, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY EFFICACY DATA, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY MEDICAL GRADE, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY LATE GERIATRIC BLOOD LINES (76-85), 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY GERIATRIC BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY PEDIATRIC BLOOD LINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY CHILD BLOOD LINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY INFANT BLOOD LINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY TODDLER BLOOD LINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY PEDIATRIC BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY DIALYSIS CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY INDEPENDENT DIALYSIS CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY NETWORKED DIALYSIS CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY DIALYSIS CLINICS, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY HOME HEMODIALYSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY ASSISTED HOME HEMODIALYSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY REMOTE HOME HEMODIALYSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY HOME HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY TERTIARY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY ADVANCED HEMODIALYSIS BLOOD LINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY HIGH EFFICIENCY BLOOD LINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY HIGH FLUX BLOOD LINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY LOW FLUX BLOOD LINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY ADVANCED HEMODIALYSIS BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY STANDARD HEMODIALYSIS BLOOD LINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY ARTERIOVENOUS (AV) FISTULA BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY ARTERIOVENOUS (AV) GRAFT BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY CENTRAL VENOUS CATHETER (CVC) BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY MATERIAL TYPE, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY POLYURETHANE BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY POLYVINYL CHLORIDE (PVC) BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY SILICONE BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY ADULT BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY GERIATRIC BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY EARLY GERIATRIC BLOOD LINES (65-75), 2018-2030 (USD MILLION)
TABLE 89. AMERICAS BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY LATE GERIATRIC BLOOD LINES (76-85), 2018-2030 (USD MILLION)
TABLE 90. AMERICAS BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY MEDICAL GRADE, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY PEDIATRIC BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 92. AMERICAS BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 93. AMERICAS BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY DIALYSIS CLINICS, 2018-2030 (USD MILLION)
TABLE 94. AMERICAS BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY HOME HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 96. AMERICAS BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 97. AMERICAS BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY ADVANCED HEMODIALYSIS BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 98. AMERICAS BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY ARTERIOVENOUS (AV) FISTULA BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY ARTERIOVENOUS (AV) GRAFT BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY CENTRAL VENOUS CATHETER (CVC) BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY MATERIAL TYPE, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY POLYURETHANE BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY POLYVINYL CHLORIDE (PVC) BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY SILICONE BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY ADULT BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY GERIATRIC BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY EARLY GERIATRIC BLOOD LINES (65-75), 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY LATE GERIATRIC BLOOD LINES (76-85), 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY MEDICAL GRADE, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY PEDIATRIC BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY DIALYSIS CLINICS, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY HOME HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY ADVANCED HEMODIALYSIS BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY ARTERIOVENOUS (AV) FISTULA BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY ARTERIOVENOUS (AV) GRAFT BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY CENTRAL VENOUS CATHETER (CVC) BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY MATERIAL TYPE, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY POLYURETHANE BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY POLYVINYL CHLORIDE (PVC) BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY SILICONE BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY ADULT BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 130. BRAZIL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY GERIATRIC BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 131. BRAZIL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY EARLY GERIATRIC BLOOD LINES (65-75), 2018-2030 (USD MILLION)
TABLE 132. BRAZIL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY LATE GERIATRIC BLOOD LINES (76-85), 2018-2030 (USD MILLION)
TABLE 133. BRAZIL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY MEDICAL GRADE, 2018-2030 (USD MILLION)
TABLE 134. BRAZIL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY PEDIATRIC BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 135. BRAZIL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 136. BRAZIL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY DIALYSIS CLINICS, 2018-2030 (USD MILLION)
TABLE 137. BRAZIL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY HOME HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 138. BRAZIL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 139. BRAZIL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 140. BRAZIL BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY ADVANCED HEMODIALYSIS BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 141. CANADA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 142. CANADA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY ARTERIOVENOUS (AV) FISTULA BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 143. CANADA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY ARTERIOVENOUS (AV) GRAFT BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 144. CANADA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY CENTRAL VENOUS CATHETER (CVC) BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 145. CANADA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY MATERIAL TYPE, 2018-2030 (USD MILLION)
TABLE 146. CANADA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY POLYURETHANE BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 147. CANADA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY POLYVINYL CHLORIDE (PVC) BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 148. CANADA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY SILICONE BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 149. CANADA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 150. CANADA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY ADULT BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 151. CANADA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY GERIATRIC BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 152. CANADA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY EARLY GERIATRIC BLOOD LINES (65-75), 2018-2030 (USD MILLION)
TABLE 153. CANADA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY LATE GERIATRIC BLOOD LINES (76-85), 2018-2030 (USD MILLION)
TABLE 154. CANADA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY MEDICAL GRADE, 2018-2030 (USD MILLION)
TABLE 155. CANADA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY PEDIATRIC BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 156. CANADA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 157. CANADA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY DIALYSIS CLINICS, 2018-2030 (USD MILLION)
TABLE 158. CANADA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY HOME HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 159. CANADA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 160. CANADA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 161. CANADA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY ADVANCED HEMODIALYSIS BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 162. MEXICO BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 163. MEXICO BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY ARTERIOVENOUS (AV) FISTULA BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 164. MEXICO BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY ARTERIOVENOUS (AV) GRAFT BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 165. MEXICO BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY CENTRAL VENOUS CATHETER (CVC) BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 166. MEXICO BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY MATERIAL TYPE, 2018-2030 (USD MILLION)
TABLE 167. MEXICO BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY POLYURETHANE BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 168. MEXICO BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY POLYVINYL CHLORIDE (PVC) BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 169. MEXICO BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY SILICONE BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 170. MEXICO BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 171. MEXICO BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY ADULT BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 172. MEXICO BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY GERIATRIC BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 173. MEXICO BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY EARLY GERIATRIC BLOOD LINES (65-75), 2018-2030 (USD MILLION)
TABLE 174. MEXICO BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY LATE GERIATRIC BLOOD LINES (76-85), 2018-2030 (USD MILLION)
TABLE 175. MEXICO BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY MEDICAL GRADE, 2018-2030 (USD MILLION)
TABLE 176. MEXICO BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY PEDIATRIC BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 177. MEXICO BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 178. MEXICO BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY DIALYSIS CLINICS, 2018-2030 (USD MILLION)
TABLE 179. MEXICO BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY HOME HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 180. MEXICO BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 181. MEXICO BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 182. MEXICO BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY ADVANCED HEMODIALYSIS BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 183. UNITED STATES BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 184. UNITED STATES BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY ARTERIOVENOUS (AV) FISTULA BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 185. UNITED STATES BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY ARTERIOVENOUS (AV) GRAFT BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 186. UNITED STATES BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY CENTRAL VENOUS CATHETER (CVC) BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 187. UNITED STATES BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY MATERIAL TYPE, 2018-2030 (USD MILLION)
TABLE 188. UNITED STATES BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY POLYURETHANE BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 189. UNITED STATES BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY POLYVINYL CHLORIDE (PVC) BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 190. UNITED STATES BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY SILICONE BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 191. UNITED STATES BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 192. UNITED STATES BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY ADULT BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 193. UNITED STATES BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY GERIATRIC BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 194. UNITED STATES BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY EARLY GERIATRIC BLOOD LINES (65-75), 2018-2030 (USD MILLION)
TABLE 195. UNITED STATES BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY LATE GERIATRIC BLOOD LINES (76-85), 2018-2030 (USD MILLION)
TABLE 196. UNITED STATES BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY MEDICAL GRADE, 2018-2030 (USD MILLION)
TABLE 197. UNITED STATES BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY PEDIATRIC BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 198. UNITED STATES BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 199. UNITED STATES BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY DIALYSIS CLINICS, 2018-2030 (USD MILLION)
TABLE 200. UNITED STATES BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY HOME HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 201. UNITED STATES BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 202. UNITED STATES BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 203. UNITED STATES BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY ADVANCED HEMODIALYSIS BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 204. UNITED STATES BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 205. ASIA-PACIFIC BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 206. ASIA-PACIFIC BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY ARTERIOVENOUS (AV) FISTULA BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 207. ASIA-PACIFIC BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY ARTERIOVENOUS (AV) GRAFT BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 208. ASIA-PACIFIC BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY CENTRAL VENOUS CATHETER (CVC) BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 209. ASIA-PACIFIC BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY MATERIAL TYPE, 2018-2030 (USD MILLION)
TABLE 210. ASIA-PACIFIC BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY POLYURETHANE BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 211. ASIA-PACIFIC BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY POLYVINYL CHLORIDE (PVC) BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 212. ASIA-PACIFIC BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY SILICONE BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 213. ASIA-PACIFIC BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 214. ASIA-PACIFIC BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY ADULT BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 215. ASIA-PACIFIC BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY GERIATRIC BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 216. ASIA-PACIFIC BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY EARLY GERIATRIC BLOOD LINES (65-75), 2018-2030 (USD MILLION)
TABLE 217. ASIA-PACIFIC BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY LATE GERIATRIC BLOOD LINES (76-85), 2018-2030 (USD MILLION)
TABLE 218. ASIA-PACIFIC BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY MEDICAL GRADE, 2018-2030 (USD MILLION)
TABLE 219. ASIA-PACIFIC BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY PEDIATRIC BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 220. ASIA-PACIFIC BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 221. ASIA-PACIFIC BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY DIALYSIS CLINICS, 2018-2030 (USD MILLION)
TABLE 222. ASIA-PACIFIC BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY HOME HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 223. ASIA-PACIFIC BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 224. ASIA-PACIFIC BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 225. ASIA-PACIFIC BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY ADVANCED HEMODIALYSIS BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 226. ASIA-PACIFIC BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 227. AUSTRALIA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 228. AUSTRALIA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY ARTERIOVENOUS (AV) FISTULA BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 229. AUSTRALIA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY ARTERIOVENOUS (AV) GRAFT BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 230. AUSTRALIA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY CENTRAL VENOUS CATHETER (CVC) BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 231. AUSTRALIA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY MATERIAL TYPE, 2018-2030 (USD MILLION)
TABLE 232. AUSTRALIA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY POLYURETHANE BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 233. AUSTRALIA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY POLYVINYL CHLORIDE (PVC) BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 234. AUSTRALIA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY SILICONE BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 235. AUSTRALIA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 236. AUSTRALIA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY ADULT BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 237. AUSTRALIA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY GERIATRIC BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 238. AUSTRALIA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY EARLY GERIATRIC BLOOD LINES (65-75), 2018-2030 (USD MILLION)
TABLE 239. AUSTRALIA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY LATE GERIATRIC BLOOD LINES (76-85), 2018-2030 (USD MILLION)
TABLE 240. AUSTRALIA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY MEDICAL GRADE, 2018-2030 (USD MILLION)
TABLE 241. AUSTRALIA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY PEDIATRIC BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 242. AUSTRALIA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 243. AUSTRALIA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY DIALYSIS CLINICS, 2018-2030 (USD MILLION)
TABLE 244. AUSTRALIA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY HOME HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 245. AUSTRALIA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 246. AUSTRALIA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 247. AUSTRALIA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY ADVANCED HEMODIALYSIS BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 248. CHINA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 249. CHINA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY ARTERIOVENOUS (AV) FISTULA BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 250. CHINA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY ARTERIOVENOUS (AV) GRAFT BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 251. CHINA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY CENTRAL VENOUS CATHETER (CVC) BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 252. CHINA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY MATERIAL TYPE, 2018-2030 (USD MILLION)
TABLE 253. CHINA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY POLYURETHANE BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 254. CHINA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY POLYVINYL CHLORIDE (PVC) BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 255. CHINA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY SILICONE BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 256. CHINA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 257. CHINA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY ADULT BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 258. CHINA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY GERIATRIC BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 259. CHINA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY EARLY GERIATRIC BLOOD LINES (65-75), 2018-2030 (USD MILLION)
TABLE 260. CHINA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY LATE GERIATRIC BLOOD LINES (76-85), 2018-2030 (USD MILLION)
TABLE 261. CHINA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY MEDICAL GRADE, 2018-2030 (USD MILLION)
TABLE 262. CHINA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY PEDIATRIC BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 263. CHINA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 264. CHINA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY DIALYSIS CLINICS, 2018-2030 (USD MILLION)
TABLE 265. CHINA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY HOME HEMODIALYSIS, 2018-2030 (USD MILLION)
TABLE 266. CHINA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 267. CHINA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 268. CHINA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY ADVANCED HEMODIALYSIS BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 269. INDIA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 270. INDIA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY ARTERIOVENOUS (AV) FISTULA BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 271. INDIA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY ARTERIOVENOUS (AV) GRAFT BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 272. INDIA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY CENTRAL VENOUS CATHETER (CVC) BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 273. INDIA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY MATERIAL TYPE, 2018-2030 (USD MILLION)
TABLE 274. INDIA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY POLYURETHANE BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 275. INDIA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY POLYVINYL CHLORIDE (PVC) BLOOD LINES, 2018-2030 (USD MILLION)
TABLE 276. INDIA BLOOD LINE FOR HEMODIAFILTRATION MARKET SIZE, BY SILICONE BLOOD LINES, 2018-2030 (USD MILLION)
TABLE

Companies Mentioned

  • Asahi Kasei Corporation
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • DMed Healthcare Group Limited
  • Fresenius Medical Care AG & Co. KGaA
  • JMS Co., Ltd.
  • Medtronic plc
  • Nikkiso Co., Ltd.
  • Nipro Corporation
  • NxStage Medical, Inc. (a Fresenius Medical Care company)

Methodology

Loading
LOADING...

Related Topics

Related Reports

Medical Hemodiafiltration Machine Market by Portability (Portable Hemodiafiltration Machines, Stationary Hemodiafiltration Machines), Components (Blood Pumps, Dialyzer Units, Hemodiafilter), Modes, End User - Global Forecast 2025-2030 - Product Image

Medical Hemodiafiltration Machine Market by Portability (Portable Hemodiafiltration Machines, Stationary Hemodiafiltration Machines), Components (Blood Pumps, Dialyzer Units, Hemodiafilter), Modes, End User - Global Forecast 2025-2030

  • Report
  • 195 Pages
  • Global
From
Continuous Renal Replacement Therapy (CRRT) - Global Strategic Business Report - Product Image

Continuous Renal Replacement Therapy (CRRT) - Global Strategic Business Report

  • Report
  • 216 Pages
  • Global
From
Continuous Renal Replacement Therapy Machines (CRRT) - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Continuous Renal Replacement Therapy Machines (CRRT) - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 100 Pages
  • Global
From
Hemodialysis Bloodline Systems Market: Global Opportunity Analysis and Industry Forecast, 2024-2033 - Product Image

Hemodialysis Bloodline Systems Market: Global Opportunity Analysis and Industry Forecast, 2024-2033

  • Report
  • 260 Pages
  • Global
From
Continuous Renal Replacement Therapy Machine Market Report 2025 - Product Image

Continuous Renal Replacement Therapy Machine Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.